CCL1 and neoplasm: In this context, in murine CRC tumor models, targeting CCR8+ Tregs through either anti-CCL1 neutralizing monoclonal antibody (mAb) [95] or anti-CCR8 mAb [96] drastically reduced the tumor infiltration by Tregs while robustly enhancing the antitumor immune response.